Clinical trial · Observational
Impact of Gated PET/CT in the Diagnosis of Advanced Ovarian Cancer
Impact of Gated PET/CT on the Diagnosis of Distant Metastases of Advanced Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will be the first prospective study enrolling consecutive patients with advanced ovarian cancer to determine the prevalence of thoracic and extra-abdominal involvement in this patient group and the relative value of gated PET and CT for diagnosing extra-abdominal involvement. This study will also answer a number of other stil unanswered questions: the impact of gating and the impact of gated PET on clinical management of patients with advanced ovarian cancer. This study also individualises patients' treatment to allow patients who may benefit most form optimal surgical cytoreduction and those who are better treated by neoadjuvant
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer Stage III | Malignant Ovarian Neoplasm | CURATED_BROADER | 0.78 |
| Ovarian Cancer Stage IV | Malignant Ovarian Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET/CT | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Advanced ovarian cancer
- description
- gated PET/CT imaging
- interventionNames
- Device: PET/CT
Primary outcomes (1)
- measure
- Proportion of patients upstaged from Stage IV from Stage III by gated PET/CT
- timeFrame
- one to six months
- description
- The primary hypothesis is that the true prevalence of extra-abdominal involvement diagnosed by gated PET/CT will be higher than the prevalence deteted by CT.
Secondary outcomes (2)
- measure
- Impact of gated PET/CT images on clinical management
- timeFrame
- one to six months
- description
- Changes to planned treatment for ovarian cancer based on the detection of metastatic spead to "unexpected sites"
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female ≥18 years of age * Suspected or histologically/cytologically proven Stage III or IV epithelial ovarian, fallopian tube, and primary peritoneal cancer * Eastern Cooperative Oncology Group (ECOG) performance status ≤3 * Negative serum or urine pregnancy test in pre-menopausal women and women \< 2 years after the onset of menopause * Signed written informed consent Exclusion Criteria: * Estimated life expectancy of \<6 months * Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer * Laparotomy performed as component of staging/clinical management prior to gated PET/CT being performed. * Unable to provide informed consent
References
Publications (1)
- DERIVEDVirili F, Obermair A, Sanjida S, Nicklin JL, Garrett A, Land R, Tang A, Campbell L, Gebski V, Thomas P. Impact of gated FDG PET/CT on the staging of patients with suspected or proven newly diagnosed advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer: results from a non-randomized, phase II clinical trial. Int J Gynecol Cancer. 2026 Jan;36(1):101854. doi: 10.1136/ijgc-2024-005633. Epub 2025 Apr 19. PMID 39237158